Addex Therapeutics (ADXN) Net Income towards Common Stockholders (2018 - 2026)
Addex Therapeutics (ADXN) posted Net Income towards Common Stockholders of -$0.01 for Q1 2026, up 100.0% sequentially from -$8.6 million in Q4 2025, and down 14.81% YoY from -$0.01 in Q1 2025.
Addex Therapeutics (ADXN) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Addex Therapeutics has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$0.01 in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 14.81% year-over-year to -$0.01 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.6 million (down 177.5% YoY) and the FY2025 annual result came in at -$8.3 million, down 202.9% from the prior year.
- Net Income towards Common Stockholders improved to -$0.01 in Q1 2026 per ADXN's latest filing, from -$8.6 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $11.0 million in Q4 2024 and troughed at -$8.6 million in Q4 2025.
- A 5-year average of $81065.5 and a median of -$0.01 in 2026 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders slumped 4883570754.12% in 2022, then jumped 755.77% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at $5.1 million in 2022, then slumped by 74.69% to $1.3 million in 2023, then surged by 755.77% to $11.0 million in 2024, then slumped by 177.5% to -$8.6 million in 2025, then surged by 100.0% to -$0.01 in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$0.01, -$8.6 million, and -$0.01 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -2.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.01 |
| Dec 31, 2025 | -8.56 Mn |
| Sep 30, 2025 | -0.01 |
| Jun 30, 2025 | -0.02 |
| Mar 31, 2025 | -0.01 |
| Dec 31, 2024 | 11.05 Mn |
| Sep 30, 2024 | -0.02 |
| Jun 30, 2024 | -0.01 |
| Mar 31, 2024 | -0.03 |
| Dec 31, 2023 | 1.29 Mn |
| Sep 30, 2023 | -0.01 |
| Jun 30, 2023 | -0.01 |
| Mar 31, 2023 | -0.04 |
| Dec 31, 2022 | 5.10 Mn |
| Sep 30, 2022 | -0.09 |
| Jun 30, 2022 | -7.50 Mn |
| Mar 31, 2022 | -0.16 |
| Dec 31, 2021 | 18.36 Mn |
| Sep 30, 2021 | -0.12 |
| Jun 30, 2021 | -0.15 |